{"filing":{"accession_number":"0001104659-26-074618","cik":"0000921114","ticker":"ARMP","company_name":"Armata Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"tm2618097d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926074618/tm2618097d1_8k.htm"},"events":[{"id":11364,"run_id":9979,"accession_number":"0001104659-26-074618","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the results of the Annual Meeting of Shareholders held on June 11, 2026, including: (1) election of seven board members with vote tallies for each director; (2) non-binding advisory approval of named executive officer compensation (28,547,283 shares for); (3) shareholder approval of annual frequency for future say-on-pay votes; and (4) ratification of Ernst \u0026 Young LLP as independent auditor (29,842,514 shares for). These are standard shareholder vote results that materially inform investors about board composition and governance decisions.","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7934,"accession_number":"0001104659-26-074618","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of the Annual Meeting of Shareholders held on June 11, 2026, including: (1) election of seven board members with vote tallies for each director; (2) non-binding advisory approval of named executive officer compensation (28,547,283 shares for); (3) shareholder approval of annual frequency for future say-on-pay votes; and (4) ratification of Ernst \u0026 Young LLP as independent auditor (29,842,514 shares for). These are standard shareholder vote results that materially inform investors about board composition and governance decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:45:16.662336+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7934,"accession_number":"0001104659-26-074618","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of the Annual Meeting of Shareholders held on June 11, 2026, including: (1) election of seven board members with vote tallies for each director; (2) non-binding advisory approval of named executive officer compensation (28,547,283 shares for); (3) shareholder approval of annual frequency for future say-on-pay votes; and (4) ratification of Ernst \u0026 Young LLP as independent auditor (29,842,514 shares for). These are standard shareholder vote results that materially inform investors about board composition and governance decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:45:16.662336+00:00","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-06-16"}]}